Amneal Pharmaceuticals Inc (NYSE:AMRX) Expected to Announce Quarterly Sales of $403.26 Million

Equities research analysts expect Amneal Pharmaceuticals Inc (NYSE:AMRX) to report $403.26 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Amneal Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $382.50 million and the highest estimate coming in at $413.50 million. Amneal Pharmaceuticals posted sales of $476.49 million in the same quarter last year, which suggests a negative year over year growth rate of 15.4%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 6th.

On average, analysts expect that Amneal Pharmaceuticals will report full year sales of $1.67 billion for the current year, with estimates ranging from $1.62 billion to $1.70 billion. For the next year, analysts anticipate that the business will report sales of $1.69 billion, with estimates ranging from $1.56 billion to $1.78 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.05). The firm had revenue of $404.60 million for the quarter, compared to analyst estimates of $420.12 million. Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The business’s revenue for the quarter was down 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.24 earnings per share.

A number of research firms have recently weighed in on AMRX. Barclays set a $5.00 price target on Amneal Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, July 11th. BMO Capital Markets cut their price target on Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating for the company in a report on Tuesday, August 6th. Leerink Swann raised Amneal Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, July 22nd. Royal Bank of Canada cut Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $11.00 to $6.00 in a report on Thursday, July 11th. Finally, SunTrust Banks reissued a “buy” rating and issued a $5.00 price target on shares of Amneal Pharmaceuticals in a report on Tuesday, August 6th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $12.13.

In other Amneal Pharmaceuticals news, SVP Pradeep Bhadauria acquired 30,000 shares of the stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $2.41 per share, with a total value of $72,300.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder International Ltd Fosun acquired 1,642,300 shares of the stock in a transaction dated Monday, August 5th. The stock was acquired at an average cost of $3.04 per share, with a total value of $4,992,592.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 1,738,966 shares of company stock valued at $5,257,557. Insiders own 26.34% of the company’s stock.

Large investors have recently made changes to their positions in the company. New York State Common Retirement Fund grew its position in Amneal Pharmaceuticals by 27.3% during the first quarter. New York State Common Retirement Fund now owns 108,616 shares of the company’s stock valued at $1,539,000 after acquiring an additional 23,316 shares during the period. Meeder Asset Management Inc. grew its position in Amneal Pharmaceuticals by 785.6% during the first quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after acquiring an additional 10,347 shares during the period. Norges Bank purchased a new stake in Amneal Pharmaceuticals during the fourth quarter valued at about $18,243,000. Brinker Capital Inc. grew its position in Amneal Pharmaceuticals by 11.1% during the first quarter. Brinker Capital Inc. now owns 21,110 shares of the company’s stock valued at $299,000 after acquiring an additional 2,105 shares during the period. Finally, Principal Financial Group Inc. grew its position in Amneal Pharmaceuticals by 30.4% during the fourth quarter. Principal Financial Group Inc. now owns 16,485 shares of the company’s stock valued at $223,000 after acquiring an additional 3,843 shares during the period. 35.06% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE AMRX traded down $0.04 during trading on Monday, reaching $2.74. The company had a trading volume of 21,779 shares, compared to its average volume of 2,342,159. Amneal Pharmaceuticals has a twelve month low of $2.38 and a twelve month high of $24.48. The stock has a market capitalization of $855.40 million, a PE ratio of 2.91, a price-to-earnings-growth ratio of 0.35 and a beta of 1.41. The stock has a 50-day moving average price of $3.76 and a two-hundred day moving average price of $9.45. The company has a current ratio of 2.17, a quick ratio of 1.41 and a debt-to-equity ratio of 3.66.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Read More: Options Trading

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.